J&J, Acutus And Boston Scientific Announce Plans For Pulsed Field AF-Ablation Technologies
Executive Summary
Pulsed field ablation, which uses a controlled electrical field instead of focused heat or cold, has shown promise as a safer alternative to thermal and cryo approaches for atrial fibrillation ablation.
You may also be interested in...
Exec Chat: Biosense Webster Is Ready For Next Chapters Of The Electrophysiology Story
Medtech Insight talked to Michael Bodner, the worldwide president of Johnson & Johnson/Biosense Webster, about the company’s plans to stay number one in the cardiac ablation market. In part 1 of the interview, the medtech veteran talked about the company's plan to compete in the crowded pulsed field ablation field.
Minute Insight: Pulsed AF Trial Of Medtronic’s PulseSelect PFA System Completes Enrollment
PULSED AF is a 500-patient pivotal trial of Medtronic’s PulseSelect PFA system for treating both paroxysmal and persistent atrial fibrillation in patients who have not responded to drugs.
Boston Scientific Shoots For Cardiac Ablation Leadership With $387M Farapulse Acquisition
Boston Scientific will exercise its option to buy the remaining 73% of Farapulse, the first company to market a pulsed field cardiac ablation system.